With $29 million in the company’s pocket, biotech Libra Therapeutics launched to take on neurodegenerative disease, with three pre-clinical programs ready to roll.
Cambridge, Massachusetts-based Yumanity Therapeutics and Boston-based Proteostasis Therapeutics announced plans to merge. The combined company will operate after the deal as Yumanity Therapeutics, and will focus on protein misfolding and neurodegenerative diseases.
We now have technology to help us keep track of mundane – but crucial – tasks. From wearables to smartphones, we have unlimited opportunities to make technology work for us.
Mitsubishi Tanabe Pharma Submits New Drug Application for Edaravone to Treat ALS in the United States OSAKA, Japan, June 20, 2016 /PRNewswire/ — Mitsubishi Tanabe Pharma Corporation (MTPC) (Head Office: Osaka; President & Representative Director, CEO: Masayuki Mitsuka), today announced that a New Drug Application has been submitted to the U.S. Food and Drug […]
Biogen Inc. plans to spin off its hemophilia drug business as a publicly traded company, leaving the drugmaker to focus on developing drugs for neurodegenerative diseases.
WASHINGTON, Aug. 4, 2015 /PRNewswire-USNewswire/ — Minor League Baseball (MiLB) mascots and representatives, including MiLB President & CEO Pat O’Conner, accepted the ALS Ice Bucket Challenge, challenging all 160 teams to raise awareness and donations to fight the disease. ALS (amyotrophic lateral sclerosis) is a progressive neurodegenerative disease that affects neurons (nerve cells) in the […]